Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + rocuronium bromide + sufentanil
- Development stage
- Unknown
- Lead developer
- Affiliated Cancer Hospital of Nanjing Medical University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Propofol + rocuronium bromide + sufentanil is a pharmacological combination used for the induction and maintenance of general anesthesia, particularly in patients undergoing thoracic surgery for lung cancer, such as non-small cell lung cancer and pulmonary adenocarcinoma. Propofol is an intravenous anesthetic that enhances GABAergic neurotransmission via the GABA-A receptor to produce hypnosis. Rocuronium bromide is a non-depolarizing neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors, facilitating endotracheal intubation and providing muscle relaxation. Sufentanil is a highly potent opioid analgesic that targets mu-opioid receptors to provide perioperative pain relief and hemodynamic stability. This triplet is frequently employed by institutions like Jiangsu Cancer Hospital in clinical protocols for video-assisted thoracoscopic surgery (VATS).
- Other names
- General Anesthesiageneral anesthesia-Astes-Femoral Neck Fractures
02
Targets
Muscle-type nicotinic acetylcholine receptorGABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on propofol + rocuronium bromide + sufentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + rocuronium bromide + sufentanil.